


# Perspectives of Healthcare Providers and Patients with Relapsed/ Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies [Corrigendum]

Ailawadhi S, Biru Y, Clavreul S, et al. *Patient Preference and Adherence* 2025;19:1089–1104.

The authors have advised that Figure 5C on page 1099 contains an error. The reason provided in the second position “Too overwhelmed to commit to the option” should read “Patient has elected not to pursue any further treatment after multiple relapses”. The correct Figure 5 is as follows:



**Figure 5 (A)** Reasons why patients accepted BsAb therapy. **(B)** Reasons why HCPs did not offer BsAbs to all eligible patients with RRMM. **(C)** Reasons why patients declined BsAb therapy.

**Notes:** \*Ex-US includes patients from Japan (n=7) and Europe (n=14); EU includes France, Germany, Italy, Spain, and the UK.

**Abbreviations:** AE, adverse event; BsAb, bispecific antibody; EU, Europe; HCP, healthcare provider; RRMM, relapsed/refractory multiple myeloma.

The authors apologize for this error.